Polymer-drug conjugates as modulators of cellular apoptosis
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 2
Abstract
The successful clinical application of polymer-protein conjugates (PE Gylated enzymes and cytokines) and the promising results arising from clinical trials with polymerbound chemotherapy (eg, doxorubicin or paclitaxel) have established their potential to reduce toxicity and improve activity in chemotherapy-refractory patients. Furthermore, and more important, they have also provided a firm foundation for more sophisticated second-generation constructs that deliver the newly energing target-directed bioactive agents (eg, modulators of apoptosis, cell cycle, anti-angiogenic drugs) in addition to polymer-based drug combinations (eg, endocrine therapy and chemotherapy). This review will focus on polymer-drug conjugate modulators of cellular apoptosis to be used as single pro-poptotic (eg, cancer) or anti-apoptotic (eg, ischemia) agents or as a combination therapy.
Authors and Affiliations
Maria J. Vicent
Keywords
Related Articles
- EP ID EP681590
- DOI 10.1208/aapsj0902022
- Views 95
- Downloads 0
A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity
The online version of this article (doi:10.1208/s12248-016-9871-8) contains supplementary material, which is available to authorized users.
Animal Models of Osteoarthritis: Challenges of Model Selection and Analysis
Osteoarthritis (OA) is the most common musculoskeletal disease, affecting millions of individuals worldwide. New treatment approaches require an understanding of the pathophysiology of OA and its biomechanical, inflammat...
Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy
A solid lipid microparticle system containing budesonide was prepared by oil in water emulsification followed by spray drying. The solid lipid system was studied in terms of morphology, particle size distribution, crysta...
AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development
Therapeutic proteins (TPs) are increasingly combined with small molecules and/or with other TPs. However preclinical tools and in vitro test systems for assessing drug interaction potential of TPs such as monoclonal anti...
International Veterinary Bioequivalence Guideline Similarities and Differences Between Australia, Canada, Europe, Japan, New Zealand and the United States
Considering the diversity in physiology between species and the numerous dosage forms that exist in veterinary drug products, there are numerous complex issues that arise from the development and regulation of veterinary...